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Abstract
Background: As the field of Primary Aldosteronism (PA) becomes ever expanded, diagnosis of PA is increasingly
diagnosed by endocrinologists. With increased PA screening, many of the cases are now found in patients with
complex co-morbidities in addition to their hypertension. Post adrenalectomy renal impairment with hyperkalemia is
now increasingly seen in these complex patients, as evidenced by the numerous reports on this issue that have
appeared within the past 3 years. We present a small case series to illustrate the breadth of the problem, along
with a discussion about how such CKD/hyperkalemic events may be predicted.
Case presentation: We present three cases of primary aldosteronism with long standing hypertension (more
than 10 years) hypokalemia (2.0–3.0 mmol/l). Serum aldosterone was high with low renin activity leading to high
aldosterone to renin ratio (ARR). They underwent abdominal CT scan revealing adrenal mass and adrenal vein
sample confirmed lateralization. None of the patients had evidence of renal disease before surgery (as evident by
normal eGFR and serum creatinine). Post adrenalectomy they had reduction in the blood pressure and became
eukalemic. Serum aldosterone and renin activity were low leading to a low ARR. Case 1 developed hyperkalemia
and increased serum creatinine 6 weeks post operatively which resolved with initiation of fludrocortisone and
every attempt to discontinue fludrocortisone resulted in hyperkalemia and rising creatinine. Her hyperkalemia is
under control with oral sodium bicarbonate. Case 2 developed hyperkalemia and increasing creatinine 2 months
post operatively transiently requiring fludrocortisone and later on managed with furosemide for hyperkalemia.
Case 3 developed renal impairment and hyperkalemia 2 weeks post operatively requiring fludrocortisone.
Conclusion: Post APA resection severe hyperkalemia may be a common entity and screening should be actively
considered in high risk patients. Older age, longer duration of hypertension, impaired pre-op and post-op GFR
and higher levels of pre-op aldosterone and are all risk factors which predict the likelihood of developing
post-operative hyperkalemia. Fludrocortisone, sodium bicarbonate, loop diuretics and potassium binders can be
used for treatment. Treatment choice should be tailored to patient characteristics including fluid status, blood
pressure and serum creatinine. Potassium binders should be avoided in patients with history of recent abdominal
surgery, opioid use and constipation. Serum electrolytes and creatinine should be monitored every 1–2 weeks
after starting treatment to ensure an adequate response. Prolonged management may be necessary in some
cases and at-risk patients should be counselled as to the meaning and importance of post-operative changes in
measured renal function and potassium.
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Background
Primary aldosteronism (PA) is characterized by hyper-
tension, suppressed plasma renin levels, inappropriately
high aldosterone secretion and in some cases hypokal-
emia. PA accounts for about 10 % of hypertensive
patients [1, 2] who are known to have a higher risk of
cardiovascular disease as compared to patients with es-
sential hypertension. For those with an Aldosterone
producing adenoma (APA), adrenalectomy offers a high
rate of possible cure.
Moderate-to-severe hyperkalemia post adrenalectomy
has been described in the literature but the risk factors
and outpatient management is not very well delineated.
We describe three cases of severe post adrenalectomy
hyperkalemia requiring complex and long term therapy
and discuss the known risk factors for developing post
APA-resection hyperkalemia and suggest an approach to
outpatient endocrinology management.
Case 1
A 51 year old woman with a 12 year history of hyperten-
sion developed hypokalemia (as low as 2.2 mmol/L). Her
blood pressure was controlled with amlodipine 10 mg
once daily and she received potassium supplements to
maintain eukalemia. Her serum aldosterone was 2832
pmol/l with undetectable plasma renin activity. Her al-
dosterone to renin ratio (ARR) was therefore estimated
at greater than 28,000 pmol/l/ng/ml/h (normal less than
2000 using renin activity of 0.1 ng/ml/h to avoid over-
inflation). Her serum creatinine was 75 umol/l with
eGFR of 85 ml/min. Abdominal CT showed a 3.5 cm
low density left adrenal mass and adrenal vein sampling
confirmed left lateralization with lateralization index
values of 23:1 and 28:1 pre and post cosyntropin infu-
sion. She underwent left adrenalectomy for what was re-
ported as a 15.6 g adrenocortical adenoma on pathology.
The post-operative biochemical course is presented in
Table 1. At 2 weeks post-operative follow up, her blood
pressure was 124/80, serum potassium 4.5 mmol/L and
serum creatinine 52 umol/l without any medications.
Her serum aldosterone was less than 70 pmol/l and
renin activity of 0.36 ng/ml/h yielding ARR less than
194. However, at 6 weeks post-operative, she presented
with serum potassium of 6.7 mmol/l, serum creatinine
of 152 umol/l associated with persistent diarrhea (deter-
mined to be non-infectious) and clinical volume deple-
tion. After fluid resuscitation she was started on
fludrocortisone 0.1 mg daily and up-titrated to 0.1 mg
bid over a 1-week period. At the higher fludrocortisone
dose she became normokalemic and her serum creatin-
ine decreased to 134 umol/l (Table 1). One month later,
her serum potassium continued to be 4.8 mmol/l and
serum creatinine 112 umol/l and so a dose reduction in
fludrocortisone was attempted but at 0.1 mg per day,
her potassium promptly rose to 5.6 mmol/l with creatin-
ine 140 umol/l. Hyperkalemia persisted in the fluid re-
plete state. She was not on any medications causing
hyperkalemia. In the context for fludrocortisone respon-
sive hyperkalemia we did not calculate TTKG (trans
tubular potassium gradient). The fludrocortisone dose
was increased again with similar normalization of potas-
sium and drop in serum creatinine but her resultant
blood pressures rose to 160/100.
Another attempt was made to decrease the fludrocor-
tisone to 0.1 mg daily which was initially tolerable but
by 2 months on this dose, her serum potassium was
again found to be 6.4 mmol/l with creatinine 152 umol/
l. This was transiently treated with higher dose fludro-
cortisone but the patient felt unwell on the medication,
complaining of abdominal pain and so the drug was
stopped in favour of furosemide 20 mg daily. Off of the
fludrocortisone, her blood pressures were 135/88 but
there was resultant hyponatremia, mild hyperkalemia
and a sharp rise in serum creatinine to 188 umol/l and
so the furosemide was stopped in favour of a return to
fludrocortisone once more. Again, her potassium nor-
malized to 4.5 mmo/l with drop in serum creatinine to
127 umol/l. Nephrology was consulted and the patient
started on sodium bicarbonate 650 mg tid with cessation
of fludrocortisone. During the last 8 months of such
Table 1 (Case1) Changes in Serum creatinine, potassium and blood pressure relative to medications. (Abbreviations: Bicarb- Bicarbonate)
Follow up period Drugs Creatinine umol/l Potassium mmol/l Blood pressure
2 weeks None 52 4.5 124/80
6 weeks None 152 6.7 -
10 weeks Fludrocortisone 0.1 mg bid 112 4.8 140/96
14 weeks Fludrocortisone 0.1 mg daily 140 5.6 -
5 months Fludrocortisone 0.1 mg bid 121 4.7 160/100
6 months Fludrocortisone 0.1 mg daily 152 6.4 -
7 months Furosemide 20 mg daily 188 5.1 -
8 months Sodium bicarb. 650 mg tid 160 5.5 -
16 months Sodium bicarb. 650 mg tid 160 5.2 122/88
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therapy, her blood pressures have been normal (122/88),
potassium levels have been near-normal (5.2 mmol/l)
with stable renal function (creatinine 160 umol/l, eGFR
31 ml/min).
Case 2
A 60 year old man with a 30 year history of hyperten-
sion and serum potassium as low as 2.9 mmol/l was
referred for assessment. At presentation he required
five antihypertensive agents to control his blood pres-
sure which ranged from 130-150/80-100. His medica-
tions were perindopril 8 mg once daily, irbesartan/
hydrochlorothiazide 300/25 mg once daily, nifedipine
60 mg twice daily and carvedilol 6.25 mg twice daily.
After temporarily stopping carvedilol, irbesartan/hydro-
chlorothiazide and perindopril, his serum aldosterone
was 1041 pmol/l with plasma renin activity of 0.2 ng/l/s
yielding an aldosterone to renin ratio (ARR) of 5205
pmol/l/ng/ml/h (normal less than 2000). CT abdomen
showed a multinodular left adrenal gland with a 1.3 cm
dominant nodule. Adrenal vein sampling (AVS) showed
left lateralization with lateralization indices of 4:1 and 12:1
pre and post cosyntropin infusion. Preoperative serum
creatinine and GFR were 77 umol/l and 60 ml/min re-
spectively. He underwent left adrenalectomy for 1.5 cm
adrenocortical adenoma in the setting of background ad-
renal hyperplasia. At 4 weeks follow up his blood pressure
was 128/80, serum creatinine 77 umol/l, serum aldoster-
one less than 70 pmol/l with renin activity of 0.31 ng/l/s
yielding ARR of less than 225 pmol/l/ng/ml/h. At that
time his irbesartan/hydrochlorothiazide was discontin-
ued and nifedipine was reduced to 60 mg daily instead
of twice daily and he continued to take carvedilol and
perindopril. At 2 months follo up his serum potassium
was found to be 6.0 mmol/l and serum creatinine 141
umol/l. He admitted using four pills of Ibuprofen for a
fall related injury. At that visit his ACE inhibitor was
stopped. A day later his serum creatinine came down to
121 umol/l but potassium remained at 5.9 mmol/l. He
was started on fludrocortisone 0.05 mg daily. Two
months later his serum creatinine was 115 umol/l and
potassium 5.3 mmol/l. He did not have clinical signs of
volume depletion and no other apparent reason for
high potassium was found; therefore he was switched
to furosemide 20 mg once daily. He required loop diur-
etic to normalize his serum potassium for 6 months
after which it was stopped as his serum potassium
remained 4.5–4.9 mmol/l without further intervention.
At that time his only medications were nifedipine
60 mg daily and carvedilol 6.25 mg daily. At 15 months
post-operative, he was successfully weaned off of carve-
dilol and his only continuing medication was nifedipine
30 mg daily with average blood pressures of 136/90.
Case 3
A 52 year old woman with type 2 diabetes and congeni-
tal right kidney aplasia was referred with a 12 year his-
tory of hypertension and hypokalemia as low as
2.3 mmol/l. At presentation she required amlodipine
10 mg once daily, telmisartan 80 mg once daily and spir-
onolactone 25 mg once daily to maintain normotension
and eukalmeia. Off of spironolactone, her aldosterone
was 1157 pmol/l and direct renin was 3 ng/l yielding
ARR of 368 pmol/l/ng/l (normal < 60 using the newer
direct renin assay). CT abdomen showed 1.5 cm hypo-
dense left adrenal mass. AVS showed left lateralization
with lateralization index of 20:1 pre and post stimula-
tion. Preoperative GFR was 69 ml/min and serum cre-
atinine of 80 umol/l. She underwent adrenalectomy for
what was reported as 2 cm adrenal cortical mass with
no surrounding hyperplasia. Two weeks after the surgery
she presented to emergency department with intermit-
tent nausea and vomiting. Her serum potassium was
6.3 mmol/l and serum creatinine was 150 umol/l. After
fluid resuscitation her serum potassium dropped to
5.1 mmol/l but creatinine persisted at 160 umol/l. She
was started on sodium bicarbonate 650 mg bid. At
2 weeks follow up her serum creatinine was 208 umol/l
and potassium remained at 5.1 mmol/l. She did not re-
quire any more antihypertensive medications and her
blood pressure was 140/70. She was started on fludro-
cortisone 0.05 mg once daily and at 1 week follow up
lab work her serum creatinine reduced to 170 umol/l
with serum potassium of 5.2. She is currently on fludro-
cortisone 0.05 mg once daily.
Discussion
Post APA resection hyperkalemia is a well-documented
entity, however the incidence and prevalence is not de-
finitively known given the predominant reliance upon
case reports and case series for its reporting. As the
number of PA diagnoses increase with increasing visi-
bility of the PA literature, it is possible that post APA-
resection hyperkalemia will become a more common
problem and endocrinologists will need to be familiar
with the management options as severe hyperkalemia
may be life-threatening.
Three retrospective studies have attempted to define the
incidence and risk factors for post-operative hyperkalemia.
Chiang et al. studied 55 post-operative APA patients
through weekly blood testing and 16 (29.1 %) out of those
developed hyperkalemia with serum potassium levels 5.3–
6.2 mmol/l within 1 to 3 weeks of surgery [3]. In most
cases, the hyperkalemia was transient, resolving by
2 months post-operative but in several cases, the high po-
tassium persisted for longer than 9 months. Results from
the German Conn’s Registry [4] showed that of 110 pa-
tients, 18 (16 %) developed post-operative hyperkalemia,
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of whom 12 patients had transient hyperkalemia while in
six patients hyperkalemia persisted beyond 11 months.
Three out of the six patients required emergency room
treatment for serum potassium greater than 6.8 mmol/l. A
third study [5] described an incidence of post-operative
hyperkalemia approximating 10.5 % (13 out of 124 pa-
tients). In that series, 3.2 % had transient hyperkalemia
and 7.3 % had hyperkalemia that was prolonged beyond
3 months. Together, these studies from diverse popula-
tions demonstrate that hyperkalemia is not rare following
APA resection and in a small but meaningful proportion
it can be severe and prolonged.
Risk factors for post-adrenalectomy hyperkalemia
Older aged patients
Older age seems to correlate with the propensity to de-
velop post-operative hyperkalemia in patients with primary
hyperaldosteronism. Subjects aged more than 53 years old
had greater odds of developing post-op hyperkalemia than
those aged less than 53 years (OR = 15.6) as described in
the Korean study [5]. Fischer et al. noted that patients who
developed hyperkalemia were significantly older as com-
pared to normokalemic population (65 ± 9 vs. 50 ± 12 years.
P = 0.026) [4]. This theme is consistent in the study by
Chiang et al.: Patients who developed hyperkalemia were
older (56.4 ± 4 vs. 46.5 ± 10.0 year. P = 0.002). However, in
the same study risk factors were analyzed further using
multivariate regression and after backward elimination,
older age was not one of the independent risk factors
[3]. It is possible that older patients had longer duration
of hypertension with more advanced hypertensive co-
morbidities including hypertensive nephropathy.
Duration of hypertension
Duration of pre-operative hypertension has been shown
to be another potentially important risk factor for devel-
oping post adrenalectomy hyperkalemia. In the study by
Chiang et al. [3], post-op hyperkalemics had longer dur-
ation of hypertension (12.8 ± 9.3 vs. 6.7 ± 5.0 year. P =
0.013). Park [5] found that subjects with duration of
hypertension greater than 9.5 years had 10 times higher
risk of developing hyperkalemia than those with less
than 9.5 years of hypertension in an age adjusted model.
All of the three subjects presented in our report had a
lengthy duration of hypertension (> 10 years) prior to
diagnosis and surgery.
Impaired renal function
Impaired renal function is an important risk factor in
predicting post-operative hyperkalemia. The Chiang
paper demonstrated that CKD (Stages III to–V) was
30 % more prevalent in patients who ultimately devel-
oped hyperkalemia [3]. Park took a more formal ap-
proach performing a ROC analysis to determine the
most likely cut off values for pre-operative eGFR’s abil-
ity to predict post-operative hyperkalemia; an eGFR of
< 58.2 ml/min was associated with increased risk of
developing hyperkalemia (OR = 26.6 p < 0.05) [5]. Fisher
found that post-op hyperkalemics had significantly worse
pre-operative renal function (creatinine: 91umol/l [76; 114
umol/l] vs. 61umol/l [53; 76 umol/l], P = 0.001; GFR: 56 ±
17 vs. 84 ± 21 ml/min, P = 0.024) [4].
While overt pre-existing renal impairment may be a
strong factor in predicting post-operative hyperkalemia,
there is now evidence that PA itself may induce a hyper-
filtration injury that may mask renal impairment until
the operative reversal of aldosterone mediated hyper-
filtration [6]. In the first case presented above, the pa-
tient did not have any evidence of renal impairment
pre operatively but after APA resection her eGFR de-
creased until it plateaued at 30–40 ml/min. Thus it
may be that a “normal” eGFR (60–100 ml/min) in the
PA pre-operative state may actually portend underlying
nephropathy that will become evident and clinically
relevant in the post-operative period.
Ribstein et al. [7] studied 25 patients with tumoral PA.
Renal studies (urinary excretion of proteins, GFR, and
effective renal plasma flow [ERPF] were performed both
before and 6 months after adrenalectomy. A control
group consisting of patients with essential hypertension
(EH) was studied before and after 6 months of antihy-
pertensive therapy. At baseline, PA and EH patients were
similar with respect to demographic data, duration and
level of hypertension, and GFR and ERPF. Urinary excre-
tion of albumin and β2 microglobulin (a marker of
glomerular filtration) was higher in PA than EH. Adre-
nalectomy was followed by a decrease in arterial urinary
excretion of albumin and β2 microglobulin, and GFR
and ERPF. In EH, a similar decrease in pressure was as-
sociated with a decrease in albuminuria but no change
in GFR or ERPF. In patients who received a 6 months
treatment of spironolactone, both GFR and ERPF de-
creased in parallel with BP, similar to what was observed
after surgery. This data suggests that PA was associated
with relative hyperfiltration, unmasked after suppression,
removal or blockade of aldosterone excess.
A few studies have attempted to identify predictors of
decreasing eGFR after APA resection. Tanase-Nakao et
al. [8] studied patients with PA who underwent unilat-
eral adrenalectomy and were followed for 1 month post
operatively. Patients who underwent non-PA adrenalec-
tomy were studied as control. Of PA patients, 37.8 %
“developed CKD” (defined as eGFR < 60 ml/min/
1.73 m2). None of non-PA group developed CKD post
op. Of the pre op variables, logistic regression analysis
showed that lower pre-surgical eGFR and higher
aldosterone-to-renin ratios (ARR) were the independ-
ent predictors of post-op CKD in PA. Another Japanese
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study [6] prospectively described 120 patients with
APA who underwent adrenalectomy while 111 patients
with bilateral adrenal hyperplasia (BAH) received MR
antagonists. Urine albumin excretion (UAE), blood
pressure and eGFR decreased significantly at 1 month
after treatment in both arms but did not decrease fur-
ther at 12 months. Multivariate regression analysis re-
vealed that higher UAE and lower serum potassium at
initial visit were independent predictors of decreasing
eGFR after intervention.
Ribstein et al. [7] showed that baseline serum potas-
sium correlated with the post-operative change in GFR
by univariate analysis. Rossi [2] in the PAPY study pro-
vided evidence that low serum potassium at baseline
predicts albuminuria. Renicke [9] described that hypo-
kalemic PA tended to be associated with renal impair-
ment. Initial potassium concentration (odds ratio, 1.3;
95 % confidence interval, 1.0–5.2; P < 0.01), plasma al-
dosterone concentrations (P < 0.05), and presence or
absence of the hypokalemic variant of PA (P < 0.05)
were independent predictors of higher creatinine.
While hypokalemia may simply be a marker of more
severe aldosteronism, it must also be considered that
hypokalemia could actually play a pathophysiologic role
in renal impairment. Low potassium itself can cause
functional and structural defects in kidneys, such as cyst
formation, tubular vacuolization, interstitial inflamma-
tion and gradual loss of renal function [10].
Post-operative hypoaldosteronism
Connell et al. [11] described a case of a 50 year old
woman who developed hyperkalemia and acute kidney
injury 1 month after resection of APA. Her aldosterone
level was inappropriately low, given hypovolaemia and
hyperkalaemia, suggesting hypoaldosteronism (plasma
aldosterone 100 pmol/l; plasma renin activity 4.4 pg/
ml/h). Gadallah [12] reported a case in which unilateral
adrenalectomy for adrenal adenoma was followed by se-
vere hyperkalemia, marked volume depletion and un-
detectable plasma renin activity and serum aldosterone
suggesting chronic suppression of the renin-aldosterone
axis. One year later, a gradual return to normokalemia,
normotension, and normal plasma renin activity and al-
dosterone levels was achieved, indicating resolution of the
suppression of the renin-aldosterone axis.
In the German Conn’s registry post-operative hyperka-
lemia caused by suppression of the zona glomerulosa
(ZG) insufficiency was examined. They measured serum
potassium, post-operative aldosterone and trans-tubular
potassium gradient (TTKG) to determine ZG insuffi-
ciency which was defined as was defined as undetectable
plasma aldosterone level (< 97pmol/l) in the presence of
hyperkalemia (K > 5.0). Of the 18 patients who devel-
oped hyperkalemia 14 had undetectable and four had
low aldosterone levels (aldosterone level < 138 pmol/l).
In all six patients who developed persistent hyperkale-
mia, serum aldosterone level was less than 97pmol/l.
The calculation of the TTKG showed decreased values
of less than 6, in three of four evaluated hyperkalemic
patients, showing inappropriate renal response to hyper-
kalemia. The normal response to hyperkalemia is an in-
crease in aldosterone secretion leading to an increased
urinary potassium excretion, with an increase of TTKG
to greater than 10 [13]. A result of less than 6 in a
hyperkalemic patient indicates inadequate aldosterone
concentration or effect [14]. They also assessed the
contralateral gland suppression index in those patients
who had selective adrenal vein sampling (AVS) prior to
surgery (n = 77). Five of five investigated patients with
persistent hyperkalemia demonstrated a contralateral al-
dosterone/cortisol ratio suppression index of aldosterone
in the non-dominant gland less than 1 versus inferior
vena cava [4].
Taniguchi et al. [15] reported a case of a 46-year-old
woman who underwent unilateral adrenalectomy and de-
veloped episodes of severe hyperkalemia for 4 months.
Plasma aldosterone concentration (PAC) was low (102.5
pmol/l) and undetectable renin activity. Serum potassium
levels gradually decreased with concomitant increase in
PAC (162pmol/l).
It is plausible that aldosterone synthesis of adjacent
and contralateral adrenal glands is severely impaired in
some cases with primary hyperaldosteronism, as is
glucocorticoid synthesis in Cushing syndrome. Since
many instances of hyperkalemia may go undetected
post operatively, a larger series with prospective, stan-
dardized, sequential potassium measures may be
needed in order to better determine if contralateral
suppression might predict hyperkalemia.
Pre-operative mineralocorticoid receptor (MR) antagonists
MR antagonists are often administered in APA patients
to control hypokalemia. Reversal of hyperaldosteronism
after long term treatment with spironolactone (SP) has
been reported in the literature, and it appears that it has
anti-steroidogenic effect. Yoneda et al. [16] reported a
case of a 41 year old man who had a left sided APA. The
plasma renin activity (PRA) was 0.6 ng/ml/h and the
plasma aldosterone concentration (PAC) was 362 pg/ml
in the supine position. CT showed a 5 mm left sided
nodule and AVS indices showed left lateralization. The
patient received spironolactone 75 mg OD daily for
5 years and 50 mg for another 4–5 years. At 10 year
follow up after discontinuation of spironolactone, the
patient’s blood pressure, serum potassium level, and
plasma aldosterone concentration remained in the nor-
mal range. Although the left adrenal gland tumor was
still present on computed tomography after treatment,
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a furosemide and upright posture test, a captopril chal-
lenge test, and a saline loading test produced no evi-
dence of PA. Adrenal vein sampling demonstrated no
sign of lateralization.
Demura et al. [17] have shown that the aldosterone
synthetic enzyme, CYP11B2, is influenced by epigenetic
factors. Long-term treatment with spironolactone may
influence the epigenetic modulation of CYP11B2. SP
(spironolactone) not only is an MR antagonist, but also
forms SP body inclusions in cells after long-term treatment.
Histological examination of SP body-containing cells dem-
onstrates enhanced but abortive steroidogenic activity [18].
These observations suggest that MR antagonists, at
long exposure times, may actually impair aldosterone
production, something that may explain or aggravate
the post adrenalectomy hypoaldosterone state.
Park et al. [5] found that out of 124 patients, 93 were
treated with spironolactone at a mean dose of 88 mg
for mean duration of 45 days. The proportion of MR
antagonist users was not significantly different between
subjects with persistent hyperkalemia, transient hyper-
kalemia and normokalemia. Preoperative treatment
with MR antagonists did not influence the incidence of
hypoaldosteronism and hyperkalemia.
These clinical reports do not yet confirm the role of
pre-operative MR antagonists in the development of
post-operative hyperkalemia but at the very least should
emphasize the importance of immediate post-operative
discontinuation of such medications.
Management of hyperkalemia post
adrenalectomy
Post adrenalectomy hyperkalemia can be severe and
life threatening, sometimes requiring emergency treat-
ment. Preventative strategies in high risk patients
would include restricting dietary potassium intake and a
useful patient-oriented website (http://www.kidney.ca/
document.doc?id=945. https://www.kidney.org/atoz/con-
tent/potassium) may help with patient dietary education.
Reversible causes should be addressed in all patients such
as hypovolemia, urinary tract obstruction and non-
steroidal anti-inflammatory drugs and renin-angiotensin-
aldosterone-system inhibitors which can all cause aggra-
vate hyperkalemia in these patients, usually by further
decreasing an already impaired GFR. Pharmacological
therapies work mainly by potassium removal either by
binding it in gut or excreting it through kidneys.
There are several agents which promote renal excre-
tion of potassium. Fludrocortisone is traditionally the
obvious choice for hypo-aldosteronism. However, it can
be challenging to treat with fludrocortisone in the long
term on account of the risk of hypertension and periph-
eral edema and potentially worsening heart failure in pa-
tients with underlying cardiac disease. An alternate
Fig. 1 Post-adrenalectomy hyperkalemia- prediction, monitoring and treatment algorithm
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3. Impaired pre-operative GFR
4. Impaired post-operative GFR
5. Higher per-operative aldosterone level
Tahir et al. BMC Endocrine Disorders  (2016) 16:43 Page 6 of 8
approach would use furosemide and oral sodium bicar-
bonate to increase renal potassium (K) excretion. Studies
on the mechanism of distal K secretion have highlighted
the importance of renal outer-medullary K (ROMK) and
maxi-K channels in distal nephron [19]. Flow dependant
K secretion works via apical membrane stretch in the
distal nephron, which activates calcium channels, in-
creasing intracellular calcium and activation of maxi-k
and ROMK channels to facilitate potassium excretion
[20]. Distal Na delivery is however indispensable for K
secretion as it provides the electro-chemical gradient
driving for K efflux via maxi-K and ROMK. Therefore,
an alternative solution to replacing mineralocorticoid is
to increase distal nephron flow and sodium delivery via
increased Na intake (ideally with NaHCO3), increased
water intake and/or loop diuretics or carbonic anhydrase
inhibitors. Potassium binders are used to excrete potas-
sium mainly through binding in the gut. A major concern
with binders especially sodium polystyrene sulfonate is the
development of intestinal necrosis involving colon and
ileum [21]. It is a rare event, on the order of 0.2 to 0.3 %.
Binders should be avoided in patients with ileus, opiate
use and recent abdominal surgery [22]. Therefore these
agents are not recommended in the immediate post-
adrenalectomy state.
Clinical approach to management
Since there are no formal studies or guidelines to in-
form the best practices in treating hyperkalemia
post-adrenalectomy, we propose following prediction,
monitoring and treatment strategy outlined in Fig. 1.
Vigilance and early intervention with careful follow up
testing is the cornerstone of the clinical approach.
Conclusion
Post APA resection severe hyperkalemia may be a com-
mon entity and screening should be actively considered
in high risk patients. Older age, longer duration of
hypertension, impaired pre-op and post-op GFR and
higher levels of pre-op aldosterone and are all risk fac-
tors which predict the likelihood of developing post-
operative hyperkalemia (see Table 2). Treatment choice
should be tailored to patient characteristics including
fluid status, blood pressure and serum creatinine
(Table 3).
The long term cure of primary aldosterone excess and
hypertension is expected to yield renal benefits but de-
velopment of irreversible post adrenalectomy renal im-
pairment after a long duration of hypertension may
argue for earlier consideration of a PA diagnosis in
hypertensive populations. With increasing numbers pa-
tients diagnosed with PA and submitted to adrenalec-
tomy, endocrinologists will need to become familiar with
the factors that predict severe hyperkalemia and adopt
an aggressive approach to prevent life threatening hyper-
kalemic complications.
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1. Can cause/worsen hypertension
2. Can mask underlying renal disease
3. Can worsen edema, heart failure
Sodium bicarbonate 1. Can be used safely in CKD
2. Can be used early post operatively
1. Unfamiliarity with the drug
2. Not much data available regarding dosing regimen
Loop diuretics 1. Effective and familiar drug
2. Can be used in hypertensive population
1. Can worsen kidney disease by dehydration
Potassium binders 1. Can be used in CKD
2. Does not interfere with blood pressure
1. Can cause complications in post-operative
and constipated patients
Tahir et al. BMC Endocrine Disorders  (2016) 16:43 Page 7 of 8
Endocrinology, Cummings School of Medicine- University of Calgary, Alberta,
Canada.
Received: 20 February 2016 Accepted: 20 June 2016
References
1. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser
M, Young Jr WF, Montori VM. Case detection, diagnosis, and treatment of
patients with primary aldosteronism: an endocrine society clinical practice
guideline Endocrine Society. J Clin Endocrinol Metab. 2008;93(9):3266–81.
doi:10.1210/jc.2008-0104. Epub 2008 Jun 13.
2. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C,
Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ,
Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E,
Boscaro M, Pessina AC, Mantero F; PAPY Study Investigators. A prospective
study of the prevalence of primary aldosteronism in 1,125 hypertensive
patients. J Am Coll Cardiol. 2006;48(11):2293–300. Epub 2006 Nov 13.
3. Chiang WF, Cheng CJ, Wu ST, Sun GH, Lin MY, Sung CC, Lin SH. Incidence
and factors of post-adrenalectomy hyperkalemia in patients with
aldosterone producing adenoma. Clin Chim Acta. 2013;424:114–8. doi:10.
1016/j.cca.2013.05.017. Epub 2013 May 28.
4. Fischer E, Hanslik G, Pallauf A, Degenhart C, Linsenmaier U, Beuschlein F,
Bidlingmaier M, Mussack T, Ladurner R, Hallfeldt K, Quinkler M, Reincke M.
Prolonged zona glomerulosa insufficiency causing hyperkalemia in primary
aldosteronism after adrenalectomy. J Clin Endocrinol Metab. 2012;97(11):
3965–73. doi:10.1210/jc.2012-2234. Epub 2012 Aug 14.
5. Park KS, Kim JH, Ku EJ, Hong AR, Moon MK, Choi SH, Shin CS, Kim SW, Kim
SY. Clinical risk factors of postoperative hyperkalemia after adrenalectomy in
patients with aldosterone-producing adenoma. Eur J Endocrinol. 2015;
172(6):725–31. doi:10.1530/EJE-15-0074. Epub 2015 Mar 12.
6. Iwakura Y, Morimoto R, Kudo M, Ono Y, Takase K, Seiji K, Arai Y, Nakamura Y,
Sasano H, Ito S, Satoh F. Predictors of decreasing glomerular filtration rate
and prevalence of chronic kidney disease after treatment of primary
aldosteronism: renal outcome of 213 cases. J Clin Endocrinol Metab. 2014;
99(5):1593–8. doi:10.1210/jc.2013-2180. Epub 2013 Nov 27.
7. Ribstein J, Du Cailar G, Fesler P, Mimran A. Relative glomerular hyperfiltration in
primary aldosteronism. J Am Soc Nephrol. 2005;16(5):1320–5. Epub 2005 Mar 30.
8. Tanase-Nakao K, Naruse M, Nanba K, Tsuiki M, Tagami T, Usui T, Okuno H,
Shimatsu A, Hashimoto S, Katabami T, Ogo A, Okumura A, Umakoshi H,
Suzuki T. Chronic kidney disease score for predicting postoperative masked
renal insufficiency in patients with primary aldosteronism. Clin Endocrinol
(Oxf). 2014;81(5):665–70. doi:10.1111/cen.12497. Epub 2014 Jun 12.
9. Reincke M, Rump LC, Quinkler M, Hahner S, Diederich S, Lorenz R, Seufert J,
Schirpenbach C, Beuschlein F, Bidlingmaier M, Meisinger C, Holle R, Endres
S; Participants of German Conn’s Registry. Risk factors associated with a low
glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab.
2009;94(3):869–75. doi:10.1210/jc.2008-1851. Epub 2008 Dec 30.
10. Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, Catena C.
Long-term renal outcomes in patients with primary aldosteronism. JAMA.
2006;295(22):2638–45.
11. Alistair Connell & Mark Cohen. A case of severe hypoaldosteronism
following unilateral adrenalectomy for Conn’s syndrome. Endocrine
Abstracts (2013) 31 P82 | doi: 10.1530/endoabs.31.P82.
12. Gadallah MF, Kayyas Y, Boules F. Reversible suppression of the renin-
aldosterone axis after unilateral adrenalectomy for adrenal adenoma. Am J
Kidney Dis. 1998;32(1):160–3.
13. Kamel KS, Ethier JH, Richardson RM, Bear RA, Halperin ML. Urine electrolytes
and osmolality: when and how to use them. Am J Nephrol. 1990;10(2):89–102.
14. Choi MJ1, Ziyadeh FN. The utility of the transtubular potassium gradient in
the evaluation of hyperkalemia. J Am Soc Nephrol. 2008 Mar; 19(3):424–6.
doi: 10.1681/ASN.2007091017. Epub 2008 Jan 23.
15. Taniguchi R, Koshiyama H, Yamauchi M, Tanaka S, Inoue D, Sato Y, Sugawa
A, Muramatsu Y, Sasano H. A Case of Aldosterone-Producing Adenoma with
Severe Postoperative Hyperkalemia. Tohoku J Exp Med. 1998;186(3):215–23.
16. Yoneda T, Demura M, Takata H, Kometani M, Karashima S, Yamagishi M,
Takeda Y. Unilateral primary aldosteronism with spontaneous remission after
long-term spironolactone therapy. J Clin Endocrinol Metab. 2012;97(4):1109–13.
doi:10.1210/jc.2011-2563. Epub 2012 Feb 15.
17. Demura M, Wang F, Yoneda T, Karashima S, Mori S, Oe M, Kometani M,
Sawamura T, Cheng Y, Maeda Y, Namiki M, Ino H, Fujino N, Uchiyama K,
Tsubokawa T, Yamagishi M, Nakamura Y, Ono K, Sasano H, Demura Y, Takeda
Y. Multiple noncoding exons 1 of nuclear receptors NR4A family (nerve growth
factor-induced clone B, Nur-related factor 1 and neuron-derived orphan
receptor 1) and NR5A1 (steroidogenic factor 1) in human cardiovascular and
adrenal tissues. J Hypertens. 2011;29(6):1185–95. doi:10.1097/HJH.
0b013e32834626bb.
18. Conn JW, Hinerman DL. Spironolactone-induced inhibition of aldosterone
biosynthesis in primary aldosteronism: morphological and functional
studies. Metabolism. 1977;26(12):1293–307.
19. Rodan AR, Huang CL. Distal potassium handling based on flow modulation
of maxi-K channel activity. Curr Opin Nephrol Hypertens. 2009;18(4):350–5.
doi:10.1097/MNH.0b013e32832c75d8.
20. Liu W, Xu S, Woda C, Kim P, Weinbaum S, Satlin LM. Effect of flow and
stretch on the [Ca2+]i response of principal and intercalated cells in cortical
collecting duct. Am J Physiol Renal Physiol. 2003;285(5):F998–F1012. Epub
2003 Jul 1.
21. McGowan CE, Saha S, Chu G, Resnick MB, Moss SF. Intestinal necrosis due to
sodium polystyrene sulfonate (Kayexalate) in sorbitol. South Med J. 2009;
102(5):493–7. doi:10.1097/SMJ.0b013e31819e8978.
22. Watson M, Abbott KC, Yuan CM. Damned if you do, damned if you don’t:
potassium binding resins in hyperkalemia. Clin J Am Soc Nephrol. 2010;
5(10):1723–6. doi:10.2215/CJN.03700410. Epub 2010 Aug 26.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Tahir et al. BMC Endocrine Disorders  (2016) 16:43 Page 8 of 8
